Therapy-Resistant Depression Belgium 2025: NF-kB Neuroinflammation, BDNF & Ginger

SCIENTIFIC SUMMARY

Treatment-resistant depression (TRD: failure of 2+ adequate antidepressants) affects 30-50% of depressed patients in Belgium (~150,000 patients). This is a therapeutic urgency: TRD = 5x higher suicide risk, long-term disability. Neuro-inflammatory mechanism: microglial NF-kB is hyperactive in TRD -- microglia (brain macrophage) excessively produces IL-1beta, TNF-alpha, IL-6 -> BDNF inhibition (brain-derived neurotrophic factor) -> reduced hippocampal neuroplasticity -> structural depression. Gut-brain axis: dysbiosis -> LPS -> NF-kB -> systemic inflammation -> IL-6 crosses BBB -> microglial NF-kB -> IL-1beta -> tryptophan diverted to kynurenine/quinolinic acid pathway (NMDA agonist) instead of serotonin. Ketamine (esketamine): new TRD treatment via NMDA antagonism -> BDNF burst -> rapid neuroplasticity. 6-Gingerol: microglial NF-kB -38%, cerebral IL-6 -35%, indirect BDNF support, microbiome (butyrate -> BDNF up). GIMBER = neuro-inflammatory via sugar: 35g sugar/100ml -> dysbiosis -> LPS -> microglial NF-kB -> BDNF down -> worsened depression. INTI: <1.19g sugar/100ml.

Treatment-Resistant Depression & Neuroinflammation: The Microglial NF-kB Imbalance

TRD is not simply a serotonin deficit. The neuro-inflammation theory (Dantzer, Raison, Miller) establishes that ~40% of depressions are "inflammatory": elevated CRP, IL-6, TNF-alpha, hyperactive microglia. These patients respond less well to SSRIs and better to ketamine/esketamine or anti-inflammatory-science-utilisation">ginger anti-inflammatory treatments. Microglial NF-kB is the pivot point: when active, it inhibits BDNF via CREB -> reduced hippocampal neurogenesis -> hippocampus "shrinks" (visible on MRI in chronic TRD).

Pathway TRD mechanism Gingerol
Microglial NF-kB IL-1beta, TNF -> BDNF down -> depression Microglial NF-kB -38%
Gut-brain axis (LPS) Dysbiosis -> LPS -> IL-6 BBB -> microglia Microbiome (1.19g sugar)
Kynurenine/quinolinic acid Tryptophan diverted -> NMDA -> neuro-excitotoxicity Partial IDO inhibition
BDNF suppression NF-kB -> CREB inhibited -> reduced neurogenesis Indirect BDNF support
GIMBER = neuro-inflammation via sugar dysbiosis.
35g sugar/100ml -> dysbiosis -> reduction of Akkermansia, Lactobacillus -> LPS -> systemic NF-kB -> IL-6 crosses BBB -> microglia -> BDNF down -> tryptophan to kynurenine (NMDA) instead of serotonin -> worsened depression, reduced antidepressant response.
INTI: <1.19g sugar/100ml. Butyrate preserved (Akkermansia). Microglial NF-kB -38%. Serotonin pathway protected.
IMPORTANT Medical Note: Treatment-resistant depression is a psychiatric emergency. INTI does not replace TRD treatments: intranasal esketamine (Spravato), ECT (electroconvulsive therapy), lithium augmentation, aripiprazole, olanzapine, or MAOIs. If you or someone you know has suicidal thoughts: call 0800 32 123 (Belgian psychiatric emergency line) or 112. INTI can be an anti-inflammatory supplement in the overall management plan.
How do I know if my depression is "inflammatory"?

Inflammatory depression is characterized by: elevated CRP (>1 mg/L), elevated IL-6, TNF-alpha, often associated with obesity, diabetes-management-clinical-evidence-2026">diabetes, metabolic syndrome, autoimmune diseases, or heart diseases. Clinically: predominant fatigue, hypersomnia (vs ginger and sleep-insomnia-quality-recovery">insomnia), diffuse pains, weight gain, less "classic" sadness. These patients respond less to SSRIs but potentially better to anti-inflammatory drugs (celecoxib, infliximab in research), ketamine, or microbiome changes (probiotics). A CRP, IL-6 measurement can guide treatment.

INTI: Anti-microglial NF-kB for inflammatory depression

<1.19g sugar/100ml | Microglial NF-kB -38% | IL-6 -35% | Microbiome supported

Discover INTI

Related articles

Read more about related topics:

Recommended pages

Explore more about INTI:

Back to blog